Award type :
Product Development Award (Bridging Award)
Product Development Award (Bridging Award)
Product type :
Vaccines
Vaccines
Award year :
2025
2025
Project start date :
08 / 14 / 2025
08 / 14 / 2025
Project end date :
Project duration (months) :
Development stage :
Licensure
Licensure
Target disease :
Typhoid
Typhoid
Region served :
Sub-Saharan Africa
Sub-Saharan Africa
Recipient organization / Country of funding recipient organization :
Eubiologics / Republic of Korea
Eubiologics / Republic of Korea
Collaborator(s) / Country :
Program for Appropriate Technology in Health (PATH) / USA
Program for Appropriate Technology in Health (PATH) / USA
Funding amount(KRW) :
1,778,429,294
1,778,429,294
Preceding project :
🔗Typhoid Conjugate Vaccine
🔗Typhoid Conjugate Vaccine
EuBiologics, in collaboration with PATH, is developing a competitively priced typhoid conjugate vaccine (EuTYPH-C) to address the global typhoid burden, which disproportionately impacts children under 15 in low- and middle-income countries. With previous RIGHT Foundation support, EuBiologics completed a Phase III trial in Kenya and Senegal, demonstrating non-inferiority to Typbar-TCV® with no safety concerns. The company obtained MFDS export licensure in July 2025 and expects WHO prequalification in 2026. This grant supports a 3.5-year follow-up study in Senegal assessing immune response persistence in Phase III participants, thereby satisfying post-WHO prequalification commitments.